Study of cadonilimab for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called cadonilimab for cervical cancer that has come back or spread to other parts of the body. It aims to see how well the drug works in real-world conditions for patients who haven't had many prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a female aged 18 or older.
- You have cervical cancer that is recurrent or metastatic and cannot be removed by surgery or cured with radiation and chemotherapy.
- You have had no prior systemic therapy for persistent, recurrent, or metastatic disease, or no more than 2 lines of systemic therapy in the recurrent or metastatic setting.
- Your cancer type is squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
- You must have at least one measurable tumor that can be accurately tracked over time.
- You must be willing to use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial studies whether adding cadonilimab (an immune therapy) to standard radiation can improve treatment for locally advanced cervical cancer. It may help your immune system work better against the cancer while radiation shrinks it.
This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.